文献速递慢性肾脏病急性肾损伤

基于胱抑素C与基于肌酐的eGFR之间的差异

Discrepancies between Cystatin C-Based and Creatinine-Based eGFR.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-06-20

在社区动脉粥样硬化风险研究中,13,197名美国成年人随访25年,发现eGFRcys较eGFRcr低30%的比例从第2次访视的7%增至第6次访视的23%,而eGFRcys高30%的比例稳定在3%-1%;eGFRcys低于eGFRcr与更差的肾脏相关实验室指标及后续死亡、肾衰竭、AKI和心力衰竭风险升高相关。

要点

  • eGFRcys较eGFRcr低30%的比例从1990-1992年的7%升至2016-2017年的23%。
  • eGFRcys较eGFRcr高30%的比例相对稳定在3%-1%。
  • eGFRcys低于eGFRcr者贫血更多、尿酸、FGF23和磷酸盐更高,且后续死亡、肾衰竭、AKI和心衰风险更高。

核心结论

  • eGFRcys低于eGFRcr与更差的肾脏相关实验室异常及更高的不良健康结局风险相关。

研究设计与样本

  • 社区动脉粥样硬化风险研究是一项美国成人的前瞻性队列研究,随访超过25年。
  • 共纳入13,197名个体,平均年龄57岁(标准差6),56%为女性,25%为黑人。
  • 在五次临床访视中测量eGFR差异,定义为eGFRcys较eGFRcr低30%或高30%。
  • 采用线性与逻辑回归评估eGFR差异与肾脏相关实验室参数的关联,采用Cox比例风险模型评估长期不良结局。

主要发现

  • 第2次访视(1990-1992)时7%的个体eGFRcys较eGFRcr低30%,该比例至第6次访视(2016-2017)时增至23%。
  • eGFRcys较eGFRcr高30%的比例相对稳定(3%-1%)。
  • eGFRcys较eGFRcr低30%的独立危险因素包括年龄较大、女性、非黑人种族、较高的eGFRcr、较高的体重指数、体重减轻和当前吸烟。
  • 与eGFRcr和eGFRcys值相近者相比,eGFRcys较eGFRcr低30%者贫血更多、尿酸、成纤维细胞生长因子23和磷酸盐水平更高。
  • 与eGFRcr和eGFRcys值相近者相比,eGFRcys较eGFRcr低30%者后续死亡、肾衰竭、AKI和心力衰竭风险更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent guidance suggests clinicians increase use of cystatin C for the estimation of GFR. Discrepant levels of creatinine- versus cystatin C-based eGFR (eGFRcr versus eGFRcys) can occur and might signify inaccurate estimation of GFR using creatinine alone. This study sought to enhance the knowledge of the risk factors and clinical implications of having a large eGFR discrepancy. METHODS: Participants in the Atherosclerosis Risk in Communities Study, a prospective cohort study of US adults, were followed over 25 years. eGFR discrepancy was measured at five clinical visits and defined as eGFRcys either 30% lower or higher than eGFRcr, the current clinical standard of care. The associations between eGFR discrepancies and kidney-related laboratory parameters were assessed using linear and logistic regression and long-term adverse outcomes, including kidney failure, AKI, heart failure, and death, using Cox proportional hazards models. RESULTS: Among 13,197 individuals (mean age 57 [SD 6] years, 56% women, 25% Black race), 7% had eGFRcys 30% lower than eGFRcr at visit 2 (1990-1992), and this proportion increased over time to 23% by visit 6 (2016-2017). By contrast, the percent with eGFRcys 30% higher than eGFRcr was relatively stable (3%-1%). Independent risk factors for having eGFRcys 30% lower than eGFRcr included older age, female sex, non-Black race, higher eGFRcr, higher body mass index, weight loss, and current smoking. Those with eGFRcys 30% lower than eGFRcr had more anemia and higher uric acid, fibroblast growth factor 23, and phosphate levels as well as higher risk of subsequent mortality, kidney failure, AKI, and heart failure compared with those with similar eGFRcr and eGFRcys values. CONCLUSIONS: Having eGFRcys lower than eGFRcr was associated with worse kidney-related laboratory derangements and a higher risk of adverse health outcomes. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_09_08_CJN0000000000000217.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Farrington DK, Surapaneni A, Matsushita K, et al. Discrepancies between Cystatin C-Based and Creatinine-Based eGFR. Clin J Am Soc Nephrol. 2023. PMID: 37339177. doi:10.2215/CJN.0000000000000217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。